Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma

Christos EmmanouilidesDepartment of Medical Oncology, Interbalkan Hospital, Thessaloniki, GreeceAbstract: Several studies have indicated that radioimmunotherapy is an effective and clinically relevant complementary therapeutic approach for patients with B-cell non-Hodgkin’s lymphoma (N...

Full description

Bibliographic Details
Main Author: Christos Emmanouilides
Format: Article
Language:English
Published: Dove Medical Press 2009-10-01
Series:Cancer Management and Research
Online Access:http://www.dovepress.com/review-of-90y-ibritumomab-tiuxetan-as-first-line-consolidation-radio-i-a3657